CEACAM7 Inhibitors encompass a range of chemicals that can indirectly suppress the activity of CEACAM7, a protein involved in cell adhesion, signaling, and potentially in various pathological processes. These inhibitors achieve their effects by interacting with and modulating different signaling pathways and cellular processes that CEACAM7 is associated with. A primary characteristic of these inhibitors is their ability to interfere with key signaling pathways that regulate cell growth, differentiation, and survival. Compounds like Gefitinib and Erlotinib target EGFR tyrosine kinase signaling, which is crucial in many cellular processes including those influencing cell adhesion. By inhibiting EGFR signaling, these compounds can indirectly reduce CEACAM7 activity, especially in cells where EGFR signaling is a significant regulator of cell adhesion and communication. Similarly, broad-spectrum inhibitors like Sorafenib and Dasatinib, which target multiple kinases, can affect various signaling pathways, potentially suppressing CEACAM7 activity in these contexts.
Another significant aspect of CEACAM7 Inhibitors is their potential to modulate cellular processes related to the immune response, gene expression, and DNA repair. Compounds like Hydroxychloroquine and Tamoxifen, through their immunomodulatory and hormone receptor modulatory actions, respectively, can indirectly influence CEACAM7 activity, particularly in immune-related processes and hormone-responsive tissues. Additionally, histone deacetylase inhibitors like Trichostatin A, by affecting gene expression, can indirectly inhibit CEACAM7 activity by altering the transcriptional environment in which CEACAM7 operates.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, an EGFR tyrosine kinase inhibitor, can affect cell signaling pathways regulated by EGFR. This might indirectly inhibit CEACAM7 activity, particularly in cells where EGFR signaling influences cell adhesion. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $75.00 $121.00 | 33 | |
Erlotinib is another EGFR inhibitor. By targeting EGFR signaling, it could indirectly reduce CEACAM7 activity or expression in cells where this pathway is relevant. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, targets RAF, VEGFR, and PDGFR kinases. Its broad-spectrum action might indirectly affect CEACAM7 activity in various signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, affecting Src family kinases and BCR-ABL. It could indirectly inhibit CEACAM7 activity in related signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, affects cell growth and proliferation pathways. Its impact could indirectly inhibit CEACAM7, especially in processes related to cell growth regulation. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib, a proteasome inhibitor, may influence the degradation of proteins involved in cell adhesion, potentially affecting CEACAM7 activity indirectly. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $57.00 | 1 | |
Hydroxychloroquine, used in autoimmune diseases, can modulate immune responses. It might indirectly affect CEACAM7 activity, particularly in immune-related processes. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen, an estrogen receptor modulator, can influence cell signaling in hormone-responsive tissues. This might indirectly inhibit CEACAM7 activity in these contexts. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A, a histone deacetylase inhibitor, affects gene expression. By altering transcriptional regulation, it may indirectly inhibit CEACAM7 activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, specifically targets the MAPK/ERK pathway. This modulation could indirectly inhibit CEACAM7 activity, especially in cell signaling. | ||||||